Gelonghui, May 13 | Nuochengjianhua (09969.HK) announced that it achieved a total operating revenue of RMB 166 million from January to March 2024. At the same time, the company continued to raise its gross profit level. The gross margin for January-March 2024 was 85.4%, an increase of 8.1 percentage points over 77.3% in the same period last year. The total R&D investment during this period was 178 million yuan, an increase of 26.09% over the previous year.
Sales revenue of the company's core product, obutinib (INOC), continued to grow. From January to March 2024, sales revenue totaled RMB 164 million, an increase of 9% over the previous year. Entering 2024, along with the implementation of the new national health insurance catalogue, the three indications of obutinib: adult chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) patients (r/RCLL/SLL) who have received at least one treatment in the past, adult mantle cell lymphoma (MCL) patients (r/RMCL) who have received at least one treatment in the past, and adult marginal zone lymphoma (MZL) patients (r/RMZL) who have received at least one treatment in the past are all covered by medical insurance. Tinib is the first and only one approved for MZL in China The indicated BTK inhibitor was listed as a Level I recommended plan for second-line treatment of marginal zone lymphoma (MZL) by the “Chinese Society of Clinical Oncology (CSCO) Lymphoma Diagnosis and Treatment Guidelines 2024”. Furthermore, the company continues to strengthen its core business management team, continuously improve commercialization capabilities, optimize execution strategies, and provide a solid foundation for accelerated growth.
As of March 31, 2024, the company held about RMB 8.2 billion in monetary capital. Based on sufficient cash guarantees, the company will continue to advance various projects and is committed to providing more and better treatment options for patients in China and around the world.
The company's management commented, “The company is a high-tech innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D, production and commercialization capabilities, focusing on fields such as tumors and autoimmune diseases where there are huge unmet clinical needs, and developing first-in-class or best-in-class drugs with breakthrough potential in the global market.”